CoChat

Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study

Schnabel, R., Messow, C. M., Lubos, E., Espinola-Klein, C., Rupprecht, H. J., Bickel, C., Sinning, C., Tzikas, S., Keller, T., Genth-Zotz, S., Lackner, K. J., Munzel, T. F., Blankenberg, S. · 2008 · European Heart Journal
Cited by 130

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

AIMS: In primary prevention, the adipocytokine adiponectin seems to be protective against diabetes mellitus and cardiovascular disease. Data in patients with manifest coronary artery disease (CAD) are scant stimulating the investigation of the association of adiponectin concentrations and cardiovascular outcome in a prospective CAD cohort. METHODS AND RESULTS: In 1890 consecutive patients with documented CAD [1130 with stable angina (SAP) and 760 with acute coronary syndrome (ACS)] baseline concentrations of adiponectin were measured by enzyme-linked immuno assay. During a median follow-up of 2.5 years cardiovascular events were registered (cardiovascular deaths 70; non-fatal myocardial infarction 46). Baseline adiponectin concentrations were similar in patients presenting with SAP [9.03 microg/mL (6.7, 13.45)] or ACS [9.19 microg/mL (6.72, 13.15)], P = 0.779. Kaplan-Meier survival analysis showed a stepwise decrease in event-free survival across quartiles of adiponectin baseline concentration (P log rank = 0.0188). A similar pattern was observed in both subgroups of patients (SAP P = 0.075 and ACS P = 0.254). In univariate analyses, continuous adiponectin concentration was related to event-free survival in all patients [HR 1.02 (95% confidence interval 1.0-1.04), P = 0.012] as well as in the subgroup of SAP subjects [1.03 (1.01-1.05), P = 0.012]. The relation was less strong in the subgroup presenting with ACS [1.014 (0.99-1.04), P = 0.280]. A correlation of adiponectin with high density cholesterol (r = 0.39) and a negative relation to triglyceride levels (r = -0.22) could be described. An increase of one interquartile distance in adiponectin concentration was associated with a 1.17-fold risk for future cardiovascular events (P = 0.013), in B-type natriuretic peptide (BNP) it meant a 1.13-fold risk (P < 0.001). In the overall patient group, this risk association remained robust after the adjustment for classical risk factors, clinical presentation and cardiac medication. Only after adjustment for BNP adiponectin lost its independent predictive value. CONCLUSION: In contrast to studies including initially healthy individuals, the current prospective study demonstrates that adiponectin is associated with adverse cardiovascular outcome in patients with manifest CAD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehn009

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 130

Metadata

Authors
Schnabel, R., Messow, C. M., Lubos, E., Espinola-Klein, C., Rupprecht, H. J., Bickel, C., Sinning, C., Tzikas, S., Keller, T., Genth-Zotz, S., Lackner, K. J., Munzel, T. F., & Blankenberg, S.
Venue
European Heart Journal
Published
2008-03-01
Volume
29
Issue
5
Pages
649-657
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2131400699
Cited by
130
References
6
FWCI
12.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. https://app.cochat.ai/papers/10.1093/eurheartj/ehn009
The paper
Schnabel, R., Messow, C. M., Lubos, E., Espinola-Klein, C., Rupprecht, H. J., Bickel, C., Sinning, C., Tzikas, S., Keller, T., Genth-Zotz, S., Lackner, K. J., Munzel, T. F., & Blankenberg, S. (2008). Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehn009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.